By Fineline Cube 
Zennova Pharmaceutical announced today a strategic partnership with U.S.‑based biotech Rapafusyn Pharmaceuticals to jointly develop next‑generation non‑degrading molecular glue medicines. The collaboration will leverage Zennova’s proprietary BioCarier delivery platform to expedite the clinical development of Rapafusyn’s lead candidate RAP‑8020 and additional pipeline assets.
Partnership Highlights
| Element | Detail |
|---|---|
| Collaborators | Zennova & Rapafusyn Pharmaceuticals |
| Objective | Accelerate development of RapaGlue‑based therapeutics using BioCarier technology |
| Key Assets | RAP‑8020 (lead candidate), other RapaGlue candidates |
| Technology Synergy | BioCarier enhances oral bioavailability of BCS IV & > 1,000 Da molecules; Rapafusyn’s DEL‑derived FKBP12‑binding macrocycles target “undruggable” proteins |
Zennova’s BioCarier Platform
- Patent‑Protected delivery system optimized for low‑solubility, high‑molecular‑weight drugs.
- Proven ability to boost oral absorption of BCS IV compounds and large biologics.
- Designed to overcome formulation challenges that historically limit clinical translation.
Rapafusyn’s RapaGlue Modality
- Molecular glue technology that coerces protein‑protein interactions, enabling degradation of previously “undruggable” targets such as transcription factors and transmembrane proteins.
- Built on large DNA‑encoded libraries (DELs) of rationally designed FKBP12‑binding macrocyclic peptides.
- Expansive pipeline across oncology, immunology, nephrology, and pain therapeutics.
Combined Strategy
| Stage | Action | Impact |
|---|---|---|
| Discovery & Lead Optimization | Rapafusyn’s RapaGlue candidates | Target novel protein classes |
| Formulation & Delivery | Zennova’s BioCarier | Enhance oral bioavailability, reduce dosing frequency |
| Preclinical & Clinical Development | Joint effort | Accelerate regulatory milestones, reduce attrition |
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech